TSXV: ACB
VANCOUVER, March 23, 2017 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) is pleased to announce the appointment of Dr. Barry Waisglass as Medical Director.
Dr. Waisglass, a general practitioner, is one of Canada's most experienced physicians in the clinical use of medical cannabis and cannabinoids. As Aurora's Medical Director, his responsibilities include advising the Company with respect to emerging issues and opportunities with respect to medical cannabis, representing Aurora at Canadian and global medical and cannabis conferences, liaising with medical associations and colleges, participating in the development of new products and new delivery mechanisms, as well as supporting the Company's international market development initiatives.
Prior to his move to Aurora, Dr. Waisglass served as Medical Director for Canadian Cannabis Clinics and CanvasRx, the country's largest network of cannabis medical clinics and cannabis counseling centres. In this role, he provided training to other physicians, and treated patients affected by a wide range of health conditions, including chronic pain, fibromyalgia, mood disorders, spasticity caused by multiple sclerosis, chemotherapy-induced nausea, appetite disorders and epilepsy.
Dr. Waisglass, who received his degree in medicine from the University of Ottawa, has undergone additional professional training in psychotherapy and psychiatric medicine. He is currently a member of the College of Physicians and Surgeons of Ontario, the Canadian Medical Association, and the Ontario Medical Association.
"Barry is an important, strategic, and timely addition, as we expand our operations in Canadaand internationally, and we are delighted that he is joining the Aurora team," said Terry Booth, CEO. "He is a deeply respected and widely-consulted clinical expert in the use of cannabis as medicine, and brings invaluable new insights and capabilities to our Company's exceptional management team."